OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 16,720 Shares

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 16,720 shares of OS Therapies stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the transaction, the insider now owns 2,531,211 shares in the company, valued at approximately $17,060,362.14. This trade represents a 0.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

OS Therapies Stock Down 28.4 %

Shares of NYSE OSTX opened at $2.95 on Friday. OS Therapies Inc has a twelve month low of $1.58 and a twelve month high of $7.00. The business’s fifty day moving average price is $3.32.

Institutional Trading of OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC bought a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,045 shares of the company’s stock, valued at approximately $28,000.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of OS Therapies in a report on Wednesday. Maxim Group lifted their price objective on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.